使用患者门户网站筛查患者开始服用新药后的症状。

IF 1.7 3区 医学 Q3 HEALTH CARE SCIENCES & SERVICES Journal of Patient Safety Pub Date : 2024-10-01 Epub Date: 2024-08-08 DOI:10.1097/PTS.0000000000001264
Sonam Shah, Alejandra Salazar, Samuel Bennett, Aneesha Fathima, Renuka Kandikatla, Tewodros Eguale, Maria Mirica, Pamela Garabedian, Lynn A Volk, Adam Wright, Gordon D Schiff
{"title":"使用患者门户网站筛查患者开始服用新药后的症状。","authors":"Sonam Shah, Alejandra Salazar, Samuel Bennett, Aneesha Fathima, Renuka Kandikatla, Tewodros Eguale, Maria Mirica, Pamela Garabedian, Lynn A Volk, Adam Wright, Gordon D Schiff","doi":"10.1097/PTS.0000000000001264","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Conduct systematic proactive pharmacovigilance screening for symptoms patients experienced after starting new medications using an electronic patient portal. We aimed to design and test the feasibility of the system, measure patient response rates, provide any needed support for patients experiencing potentially drug-related problems, and describe types of symptoms and problems patients report.</p><p><strong>Methods: </strong>We created an automated daily report of all new prescriptions, excluding likely non-new and various over-the-counter meds, and sent invitations via patient portal inviting patients to inquire if they had started the medication, and if \"yes,\" inquire if they had they experienced any new symptoms that could be potential adverse drug effects. Reported symptoms were classified by clinical pharmacists using SOC MeDra taxonomy, and patients were offered follow-up and support as desired and needed.</p><p><strong>Results: </strong>Of 11,724 included prescriptions for 9360 unique patients, 2758 (29.4%) patients responded. Of 2616 unique medication starts, patients reported at least 1 new symptom that represented a potential adverse drug reaction (ADR) in 678/2616 (25.9%). Nearly one-third of those experiencing new symptoms (30.3%) reported 2 or more new symptoms after initiating the drug. GI disorders accounted for 30% of the total reported ADRs.</p><p><strong>Conclusions: </strong>Systematic portal-based surveillance for potential adverse drug reactions was feasible, had higher response rates than other methods (such as automated interactive phone calling), and uncovered rates of potential ADRs (roughly 1 in 4 patients) consistent with other methods/studies.</p>","PeriodicalId":48901,"journal":{"name":"Journal of Patient Safety","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Using a Patient Portal to Screen Patients for Symptoms After Starting New Medications.\",\"authors\":\"Sonam Shah, Alejandra Salazar, Samuel Bennett, Aneesha Fathima, Renuka Kandikatla, Tewodros Eguale, Maria Mirica, Pamela Garabedian, Lynn A Volk, Adam Wright, Gordon D Schiff\",\"doi\":\"10.1097/PTS.0000000000001264\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Conduct systematic proactive pharmacovigilance screening for symptoms patients experienced after starting new medications using an electronic patient portal. We aimed to design and test the feasibility of the system, measure patient response rates, provide any needed support for patients experiencing potentially drug-related problems, and describe types of symptoms and problems patients report.</p><p><strong>Methods: </strong>We created an automated daily report of all new prescriptions, excluding likely non-new and various over-the-counter meds, and sent invitations via patient portal inviting patients to inquire if they had started the medication, and if \\\"yes,\\\" inquire if they had they experienced any new symptoms that could be potential adverse drug effects. Reported symptoms were classified by clinical pharmacists using SOC MeDra taxonomy, and patients were offered follow-up and support as desired and needed.</p><p><strong>Results: </strong>Of 11,724 included prescriptions for 9360 unique patients, 2758 (29.4%) patients responded. Of 2616 unique medication starts, patients reported at least 1 new symptom that represented a potential adverse drug reaction (ADR) in 678/2616 (25.9%). Nearly one-third of those experiencing new symptoms (30.3%) reported 2 or more new symptoms after initiating the drug. GI disorders accounted for 30% of the total reported ADRs.</p><p><strong>Conclusions: </strong>Systematic portal-based surveillance for potential adverse drug reactions was feasible, had higher response rates than other methods (such as automated interactive phone calling), and uncovered rates of potential ADRs (roughly 1 in 4 patients) consistent with other methods/studies.</p>\",\"PeriodicalId\":48901,\"journal\":{\"name\":\"Journal of Patient Safety\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Patient Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/PTS.0000000000001264\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Patient Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/PTS.0000000000001264","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

目标:利用电子患者门户网站对患者在开始服用新药后出现的症状进行系统的主动药物警戒筛查。我们旨在设计并测试该系统的可行性,测量患者的反应率,为遇到可能与药物相关问题的患者提供所需的支持,并描述患者报告的症状和问题类型:我们创建了一份所有新处方的自动每日报告,其中不包括可能的非新处方和各种非处方药,并通过患者门户网站发送邀请函,请患者询问他们是否已开始用药,如果 "是",则询问他们是否出现了任何可能是潜在药物不良反应的新症状。临床药剂师使用 SOC MeDra 分类法对患者报告的症状进行分类,并根据患者的意愿和需要为其提供随访和支持:在 9360 名患者的 11724 份处方中,2758 名患者(29.4%)做出了回应。在 2616 例开始用药的患者中,678/2616 例(25.9%)患者报告了至少一种代表潜在药物不良反应 (ADR) 的新症状。在出现新症状的患者中,近三分之一(30.3%)的患者在用药后报告了 2 个或更多新症状。消化道疾病占报告不良反应总数的30%:基于门户网站的潜在药物不良反应系统监测是可行的,其响应率高于其他方法(如自动交互式电话呼叫),发现潜在药物不良反应的比例(大约每 4 名患者中就有 1 例)与其他方法/研究一致。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Using a Patient Portal to Screen Patients for Symptoms After Starting New Medications.

Objective: Conduct systematic proactive pharmacovigilance screening for symptoms patients experienced after starting new medications using an electronic patient portal. We aimed to design and test the feasibility of the system, measure patient response rates, provide any needed support for patients experiencing potentially drug-related problems, and describe types of symptoms and problems patients report.

Methods: We created an automated daily report of all new prescriptions, excluding likely non-new and various over-the-counter meds, and sent invitations via patient portal inviting patients to inquire if they had started the medication, and if "yes," inquire if they had they experienced any new symptoms that could be potential adverse drug effects. Reported symptoms were classified by clinical pharmacists using SOC MeDra taxonomy, and patients were offered follow-up and support as desired and needed.

Results: Of 11,724 included prescriptions for 9360 unique patients, 2758 (29.4%) patients responded. Of 2616 unique medication starts, patients reported at least 1 new symptom that represented a potential adverse drug reaction (ADR) in 678/2616 (25.9%). Nearly one-third of those experiencing new symptoms (30.3%) reported 2 or more new symptoms after initiating the drug. GI disorders accounted for 30% of the total reported ADRs.

Conclusions: Systematic portal-based surveillance for potential adverse drug reactions was feasible, had higher response rates than other methods (such as automated interactive phone calling), and uncovered rates of potential ADRs (roughly 1 in 4 patients) consistent with other methods/studies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Patient Safety
Journal of Patient Safety HEALTH CARE SCIENCES & SERVICES-
CiteScore
4.60
自引率
13.60%
发文量
302
期刊介绍: Journal of Patient Safety (ISSN 1549-8417; online ISSN 1549-8425) is dedicated to presenting research advances and field applications in every area of patient safety. While Journal of Patient Safety has a research emphasis, it also publishes articles describing near-miss opportunities, system modifications that are barriers to error, and the impact of regulatory changes on healthcare delivery. This mix of research and real-world findings makes Journal of Patient Safety a valuable resource across the breadth of health professions and from bench to bedside.
期刊最新文献
Response to the Letter to the Editor by Cioccari et al. Implementation and Evaluation of Clinical Decision Support for Apixaban Dosing in a Community Teaching Hospital. Patient Harm Events and Associated Cost Outcomes Reported to a Patient Safety Organization. Advancing Patient Safety: Harnessing Multimedia Tools to Alleviate Perioperative Anxiety and Pain. Translation and Comprehensive Validation of the Hebrew Survey on Patient Safety Culture (HSOPS 2.0).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1